Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Rybrevant (amivantamab) 350mg concentrate for solution for infusion {equilateral_black_triangle}

Active Ingredient:
amivantamab
Company:  
Janssen-Cilag Ltd (a Johnson & Johnson Company) See contact details
ATC code: 
L01FX18
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Risk Materials HCP Med Info
{arrow_left}
{arrow_right}

Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.

{pdf_link}

Rybrevant -Important Risk Minimisation Information-Guide to Dosing and Administration

{healthcare_pro_orange} For Healthcare Professionals
Information to provide guidance on Dosing and Administration of Rybrevant including Dosing Schedules and Modifications.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Janssen-Cilag Ltd (a Johnson & Johnson Company)
Company image
Address
50 - 100 Holmers Farm Way, High Wycombe, Bucks, HP12 4EG
Telephone
+44 (0)1494 567 567
Medical Information Fax
+44 (0) 1494 567 445
WWW
https://www.janssen.com/uk/
Fax
+44 (0)1494 567 568
Medical Information Direct Line
+44 (0)800 731 8450
Customer Care direct line
+44 (0)800 731 5550
Medical Information e-mail
[email protected]